Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Recruiting
Observational Study
Osteoporosis
Postmenopausal Osteoporosis
Frailty
Fragility Fractures
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 98 (estimated)
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria:
* Female sex
* Age 45 years or older
* Postmenopausal status
* Attendance at the Physical Medicine and Rehabilitation outpatient clinic
* Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation
* Ability and willingne…
Contacts